KBC Group NV reduced its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 19.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 7,085 shares of the biopharmaceutical company’s stock after selling 1,731 shares during the quarter. KBC Group NV’s holdings in Regeneron Pharmaceuticals were worth $2,664,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. Steward Partners Investment Advisory LLC increased its position in Regeneron Pharmaceuticals by 495.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 307 shares during the period. Vident Investment Advisory LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $200,000. Virtu KCG Holdings LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $206,000. AE Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $206,000. Finally, Moors & Cabot Inc. acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $217,000. Hedge funds and other institutional investors own 64.67% of the company’s stock.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $325.60, for a total value of $325,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.80% of the company’s stock.
Several equities research analysts have recently weighed in on REGN shares. Jefferies Group reiterated a “hold” rating and set a $421.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, February 2nd. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the stock an “equal weight” rating in a research report on Friday, February 9th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 28th. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Finally, Guggenheim set a $530.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $457.03.
Shares of Regeneron Pharmaceuticals Inc (NASDAQ REGN) opened at $323.04 on Wednesday. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11. The company has a market cap of $34,710.00, a price-to-earnings ratio of 31.30, a price-to-earnings-growth ratio of 1.04 and a beta of 1.47. Regeneron Pharmaceuticals Inc has a twelve month low of $313.53 and a twelve month high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $1.05. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The business’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period last year, the company posted $3.04 earnings per share. equities analysts predict that Regeneron Pharmaceuticals Inc will post 19.2 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thestockobserver.com/2018/02/21/kbc-group-nv-sells-1731-shares-of-regeneron-pharmaceuticals-inc-regn.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.